Rhenman & Partners Asset Management AB
13F Reported Value
ⓘ$810.5M
Holdings
86
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Rhenman & Partners Asset Management AB disclosed 86 positions worth $810.5M in its Form 13F-HR for Q1 2026, led by $BSX (BOSTON SCIENTIFIC CORP) at 4.8% of the equity portfolio, followed by $REGN and $LLY. During the quarter the fund opened 11 new positions and exited 19 — including a new stake in $SYK and a full exit from $VERA. The portfolio is most concentrated in Healthcare (88.8% of disclosed assets). All figures are sourced directly from Rhenman & Partners Asset Management AB’s Form 13F-HR filing with the SEC under CIK 1599882.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 79.9#49
Quality
$39.2M625,000 sh - 75.1#138
Quality
$37.2M48,100 sh - 89.3#2
Quality
$31.0M33,715 sh - 29.4
Quality
$26.1M159,760 sh - 51.3
Quality
$24.2M336,500 sh - 77.8
Quality
$23.4M167,750 sh - 63.7
Quality
$20.3M41,340 sh - 65.6
Quality
$20.0M109,100 sh - 76.6
Quality
$19.4M43,485 sh - 63.0
Quality
$18.6M1,053,450 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BOSTON SCIENTIFIC CORP$BSX | 79.9#49 | $39.2M | 625,000 |
 REGENERON PHARMACEUTICALS, INC.$REGN | 75.1#138 | $37.2M | 48,100 |
 ELI LILLY & Co$LLY | 89.3#2 | $31.0M | 33,715 |
 INSMED Inc$INSM | 29.4 | $26.1M | 159,760 |
 CVS HEALTH Corp$CVS | 51.3 | $24.2M | 336,500 |
 GILEAD SCIENCES, INC.$GILD | 77.8 | $23.4M | 167,750 |
 THERMO FISHER SCIENTIFIC INC.$TMO | 63.7 | $20.3M | 41,340 |
 BIOGEN INC.$BIIB | 65.6 | $20.0M | 109,100 |
 VERTEX PHARMACEUTICALS INC / MA$VRTX | 76.6 | $19.4M | 43,485 |
 Alignment Healthcare, Inc.$ALHC | 63.0 | $18.6M | 1,053,450 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Rhenman & Partners Asset Management AB's 86 positions.
Showing top 10 of 86 holdings.
Sector Allocation
Healthcare
$719.6M
Technology
$54.1M
Consumer Staples
$36.7M
Full Holdings — Rhenman & Partners Asset Management AB (Q1 2026)
All 86 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BSX | BOSTON SCIENTIFIC CORP | $39.2M | 4.8% | +45% | 79.9 |
| 2 | $REGN | REGENERON PHARMACEUTICALS, INC. | $37.2M | 4.6% | -22% | 75.1 |
| 3 | $LLY | ELI LILLY & Co | $31.0M | 3.8% | -20% | 89.3 |
| 4 | $INSM | INSMED Inc | $26.1M | 3.2% | +41% | 29.4 |
| 5 | $CVS | CVS HEALTH Corp | $24.2M | 3.0% | +0% | 51.3 |
| 6 | $GILD | GILEAD SCIENCES, INC. | $23.4M | 2.9% | +33% | 77.8 |
| 7 | $TMO | THERMO FISHER SCIENTIFIC INC. | $20.3M | 2.5% | +23% | 63.7 |
| 8 | $BIIB | BIOGEN INC. | $20.0M | 2.5% | +18% | 65.6 |
| 9 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $19.4M | 2.4% | +27% | 76.6 |
| 10 | $ALHC | Alignment Healthcare, Inc. | $18.6M | 2.3% | +4% | 63 |
| 11 |  $ISRG | INTUITIVE SURGICAL INC | $17.0M | 2.1% | -23% | 81.4 |
| 12 |  $COR | Cencora, Inc. | $16.5M | 2.0% | -17% | 59.6 |
| 13 |  $SYK | STRYKER CORP | $15.7M | 1.9% | NEW | 69.8 |
| 14 |  $ABBV | AbbVie Inc. | $15.6M | 1.9% | -35% | 59.3 |
| 15 |  $VEEV | VEEVA SYSTEMS INC | $15.0M | 1.9% | NEW | 77.8 |
| 16 |  $MCK | MCKESSON CORP | $14.6M | 1.8% | -34% | 63.7 |
| 17 |  $JAZZ | Jazz Pharmaceuticals plc | $14.3M | 1.8% | +3% | — |
| 18 |  $GH | Guardant Health, Inc. | $13.4M | 1.6% | +81% | 36.1 |
| 19 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $13.3M | 1.6% | -20% | 75.4 |
| 20 |  $EW | Edwards Lifesciences Corp | $13.1M | 1.6% | -16% | 67.6 |
| 21 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.6M | 1.6% | +23% | 25.4 |
| 22 |  $UNH | UNITEDHEALTH GROUP INC | $12.3M | 1.5% | -17% | 66.8 |
| 23 |  $PRCT | PROCEPT BioRobotics Corp | $11.9M | 1.5% | -22% | 34.8 |
| 24 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $11.7M | 1.4% | -4% | 74.1 |
| 25 |  $ABT | ABBOTT LABORATORIES | $11.5M | 1.4% | NEW | 67 |
| 26 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $11.4M | 1.4% | -25% | 60.9 |
| 27 |  $RPRX | Royalty Pharma plc | $11.2M | 1.4% | +13% | — |
| 28 |  $AXSM | Axsome Therapeutics, Inc. | $10.8M | 1.3% | -44% | 36.6 |
| 29 |  $NTRA | Natera, Inc. | $10.3M | 1.3% | +27% | 46.4 |
| 30 |  $THC | TENET HEALTHCARE CORP | $10.2M | 1.3% | -29% | 66.6 |
| 31 |  $ADPT | Adaptive Biotechnologies Corp | $10.0M | 1.2% | +19% | 35.2 |
| 32 |  $LIVN | LivaNova PLC | $9.9M | 1.2% | -18% | — |
| 33 |  $ELV | Elevance Health, Inc. | $9.5M | 1.2% | +115% | 59.4 |
| 34 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $9.1M | 1.1% | +0% | 74.4 |
| 35 |  $GKOS | GLAUKOS Corp | $9.0M | 1.1% | -60% | 39.2 |
| 36 |  $IQV | IQVIA HOLDINGS INC. | $9.0M | 1.1% | +100% | 59.7 |
| 37 |  $SNDX | Syndax Pharmaceuticals Inc | $8.9M | 1.1% | -22% | 30 |
| 38 |  $MIRM | Mirum Pharmaceuticals, Inc. | $8.6M | 1.1% | -13% | 32.7 |
| 39 |  $IDYA | IDEAYA Biosciences, Inc. | $8.5M | 1.1% | +2% | 10.5 |
| 40 |  $PNTG | Pennant Group, Inc. | $8.4M | 1.0% | -23% | 56.4 |
| 41 |  $NUVL | Nuvalent, Inc. | $8.3M | 1.0% | -50% | — |
| 42 |  $WAY | Waystar Holding Corp. | $8.3M | 1.0% | NEW | 71.4 |
| 43 |  $AVR | Anteris Technologies Global Corp. | $8.0M | 1.0% | +16% | — |
| 44 |  $MDT | Medtronic plc | $7.8M | 1.0% | -70% | — |
| 45 |  $OSCR | Oscar Health, Inc. | $7.6M | 0.9% | +154% | 70.4 |
| 46 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $7.2M | 0.9% | +29% | 30.6 |
| 47 |  $MLYS | Mineralys Therapeutics, Inc. | $7.1M | 0.9% | +85% | — |
| 48 |  $IONS | IONIS PHARMACEUTICALS INC | $7.0M | 0.9% | -41% | 37.1 |
| 49 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $6.9M | 0.8% | -17% | 26.8 |
| 50 |  $BBIO | BridgeBio Pharma, Inc. | $6.7M | 0.8% | +11% | 31.7 |
| 51 |  $APGE | Apogee Therapeutics, Inc. | $6.3M | 0.8% | NEW | — |
| 52 |  $GPCR | Structure Therapeutics Inc. | $6.2M | 0.8% | -13% | — |
| 53 |  $CAH | CARDINAL HEALTH INC | $5.7M | 0.7% | NEW | 58.6 |
| 54 |  $EHC | Encompass Health Corp | $5.4M | 0.7% | -62% | 68.9 |
| 55 |  $AMGN | AMGEN INC | $5.3M | 0.7% | -58% | 79.5 |
| 56 |  $VKTX | Viking Therapeutics, Inc. | $5.2M | 0.6% | +93% | — |
| 57 |  $NRIX | Nurix Therapeutics, Inc. | $4.9M | 0.6% | -42% | 13.2 |
| 58 |  $ALKS | Alkermes plc. | $4.7M | 0.6% | +0% | — |
| 59 |  $CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $4.5M | 0.6% | +18% | 47.1 |
| 60 |  $MLTX | MoonLake Immunotherapeutics | $4.5M | 0.6% | -34% | — |
| 61 |  $KRYS | Krystal Biotech, Inc. | $4.3M | 0.5% | -33% | 75.9 |
| 62 |  $DOCS | Doximity, Inc. | $4.3M | 0.5% | -51% | 77.5 |
| 63 |  $NKTR | NEKTAR THERAPEUTICS | $4.2M | 0.5% | NEW | 10.2 |
| 64 |  $DNLI | Denali Therapeutics Inc. | $3.8M | 0.5% | +99% | — |
| 65 |  $STVN | Stevanato Group S.p.A. | $3.8M | 0.5% | +87% | — |
| 66 |  $RLAY | Relay Therapeutics, Inc. | $3.6M | 0.4% | -22% | 12.7 |
| 67 |  $COO | COOPER COMPANIES, INC. | $3.6M | 0.4% | -85% | 55.8 |
| 68 |  $SION | Sionna Therapeutics, Inc. | $3.5M | 0.4% | NEW | — |
| 69 |  $ASND | Ascendis Pharma A/S | $3.4M | 0.4% | +0% | 41.5 |
| 70 |  $DHR | DANAHER CORP /DE/ | $3.4M | 0.4% | -82% | 63.9 |
| 71 |  $PODD | INSULET CORP | $2.9M | 0.4% | -77% | 70.4 |
| 72 |  $A | AGILENT TECHNOLOGIES, INC. | $2.8M | 0.3% | +25% | 64.6 |
| 73 |  $STOK | Stoke Therapeutics, Inc. | $2.7M | 0.3% | -62% | 53.4 |
| 74 |  $ESPR | Esperion Therapeutics, Inc. | $2.7M | 0.3% | NEW | 34.3 |
| 75 |  $IMCR | Immunocore Holdings plc | $2.6M | 0.3% | -44% | — |
| 76 |  $OCUL | OCULAR THERAPEUTIX, INC | $2.6M | 0.3% | +15% | 12.8 |
| 77 |  $STE | STERIS plc | $2.5M | 0.3% | +92% | — |
| 78 |  $VCEL | Vericel Corp | $2.3M | 0.3% | -40% | 46 |
| 79 |  $KURA | Kura Oncology, Inc. | $2.2M | 0.3% | -69% | 9.1 |
| 80 |  $CI | Cigna Group | $2.1M | 0.3% | -79% | 66.8 |
| 81 |  $BTSG | BrightSpring Health Services, Inc. | $2.1M | 0.3% | -75% | 64.3 |
| 82 |  $XENE | Xenon Pharmaceuticals Inc. | $1.6M | 0.2% | -80% | 12.9 |
| 83 |  $ALGN | ALIGN TECHNOLOGY INC | $1.3M | 0.2% | -92% | 58.2 |
| 84 |  $NVCR | NovoCure Ltd | $763,000 | 0.1% | NEW | — |
| 85 |  $ATEC | Alphatec Holdings, Inc. | $761,600 | 0.1% | +250% | 37.7 |
| 86 |  $CMPX | Compass Therapeutics, Inc. | $608,948 | 0.1% | NEW | — |
New Positions (11)
$SYK STRYKER CORP$15.7M$VEEV VEEVA SYSTEMS INC$15.0M$ABT ABBOTT LABORATORIES$11.5M$WAY Waystar Holding Corp.$8.3M$APGE Apogee Therapeutics, Inc.$6.3M$CAH CARDINAL HEALTH INC$5.7M$NKTR NEKTAR THERAPEUTICS$4.2M$SION Sionna Therapeutics, Inc.$3.5M$ESPR Esperion Therapeutics, Inc.$2.7M$NVCR NovoCure Ltd$763,000$CMPX Compass Therapeutics, Inc.$608,948Exited Positions (19)
$VERA Vera Therapeutics, Inc.
$PEN Penumbra Inc
$APLS Apellis Pharmaceuticals, Inc.
$ACLX Arcellx, Inc.
$BRKR BRUKER CORP
$RYTM RHYTHM PHARMACEUTICALS, INC.
$RDNT RadNet, Inc.
$INSP Inspire Medical Systems, Inc.
$JANX Janux Therapeutics, Inc.
$PRVA Privia Health Group, Inc.
$CYTK CYTOKINETICS INC
$XNCR Xencor Inc
$CNTA Centessa Pharmaceuticals plc
$TGTX TG THERAPEUTICS, INC.
$BNTX BioNTech SEBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Rhenman & Partners Asset Management AB including:
Track Rhenman & Partners Asset Management AB's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Rhenman & Partners Asset Management AB and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Rhenman & Partners Asset Management AB
13F Pro is an AI hedge fund tracker and stock research platform. For Rhenman & Partners Asset Management AB (SEC CIK: 1599882), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Rhenman & Partners Asset Management AB's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.